글로벌 편두통 시장 – 2029년까지의 산업 동향 및 예측

글로벌 편두통 시장 분석 및 규모

최근 몇 년 동안 편두통 시장은 예측 기간 동안 빠르게 성장할 것으로 예상됩니다. 세계보건기구에 따르면 편두통은 세계에서 19번째로 흔한 장애 원인입니다. 편두통 환자는 이 질환이 없는 사람보다 처방약을 두 배나 많이 복용하고 의사와 응급실을 두 배나 자주 방문합니다. 편두통 환자는 또한 의료 서비스에 상당히 더 많은 비용을 지출했습니다. 편두통 환자는 편두통이 없는 사람보다 처방약을 2.5배 더 많이 복용하고 진단 검사 와 서비스도 여섯 배나 많이 받는 것으로 관찰되었습니다. 편두통 발생률이 증가함에 따라 완화를 위해 더 많은 치료법이 사용되고 있으며, 이는 전체 시장을 주도하는 역할을 합니다.

• Data Bridge Market Research는 편두통 시장이 2021년에 35억 달러 규모였으며 2029년까지 48억 3,000만 달러에 도달할 것으로 예상하고 2022년부터 2029년까지의 예측 기간 동안 4.10%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

글로벌 편두통 시장 정의

편두통은 한 사람에게만 이마, 머리 옆 또는 눈 주위에 욱신거리는 통증을 유발하는 신경계 질환입니다. 메스꺼움, 구토, 광선공포증, 소리공포증과 같은 자율신경 증상이 통증과 자주 연관됩니다. 편두통은 일반적으로 환자의 병력과 증상을 살펴보고 혈액 검사와 MRI 및 CT 스캔을 수행하여 진단합니다. 증상을 완화하고 편두통 발작의 빈도와 강도를 줄이기 위해 현재 일반 의약품(OTC)과 처방 주사가 제공됩니다. 이러한 약물은 정기적으로 복용하거나 만성 통증의 발작이나 악화에 대응하여 복용합니다.

보고 범위 및 시장 세분화

편두통 시장 동향

운전자

• 편두통 유병률 증가

편두통 유병률 증가는 편두통 시장 성장의 주요 원동력입니다. 흡연 중독 증가와 알코올 소비 증가는 편두통 유병률을 높이고 예측 기간 동안 시장 역학에 영향을 미치는 주요 요인입니다.  

• 정밀의학에 대한 수요 증가

정밀 의약품에 대한 수요 증가는 시장 성장률을 높일 것입니다. 이와 함께 편두통 약물 에 대한 환불 정책의 개선은 시장 성장률을 촉진할 것입니다.

• 의료 인프라에 대한 투자 증가

편두통 시장의 성장률에 영향을 미치는 또 다른 중요한 요인은 의료 서비스 지출이 증가하고 있다는 점인데, 이는 인프라 개선에 도움이 됩니다.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the migraine market. Additionally, high disposable income and increasing demand for nerve stimulation devices to treat migraine will result in the expansion of migraine market. Along with this, rising geriatric population and the advent of calcitonin gene-related peptide (CGRP) monoclonal antibodies will enhance the growth rate of the market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the migraine market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the migraine market growth during the forecast period.

Restraints/Challenges Global Migraine Market

On the other hand, the high cost associated with the treatment of migraine will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the migraine market. Additionally, a decline in clinical visits due to COVID0-19 outbreak and procedural treatment of migraines due to social distancing norms will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This migraine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the migraine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Migraine market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Migraine Market

Several worldwide markets have been harmed by the global coronavirus pandemic. COVID-19 cases and patient care were keeping the health sector busy. During this time, the pharmaceutical and drug research industries were experiencing a surge in demand. The migraine market, on the other hand, is being impacted by the virus outbreak. Various medications for the treatment of COVID-19 were being tested by the pharmaceutical industry. In addition, migraine drug testing for COVID-19 were having a beneficial impact on the market.

During this time, there is a lot of dirge research going on. The majority of biopharmaceutical businesses use this time to create new medications. The migraine medicine industry is keeping track of drug compositions and effects. Demand will rise as a result of the considerable research into the migraine sector. In addition, in the coming years, a wider choice of medications and treatments will be available. All of these will assist the migraine market as a whole.

Recent Development

• In September 2021, FDA had approves the first and only oral CGRP receptor antagonist named QULIPTA™ (atogepant), which is specifically developed for the preventive treatment of migraine. CGRP and its receptors are used for nervous system associated with migraine pathogenesis, and CGRP levels have been found to be higher during migraine attacks in studies. QULIPTA is a once-daily medication that blocks CGRP. It comes in three different strengths including 10 mg, 30 mg, and 60 mg.

Global Migraine Market Scope

The migraine market is segmented on the basis of type, symptoms, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Episodic
• Chronic

On the basis of type, the migraine market is segmented into episodic, and chronic.

Symptoms

• Food Cravings
• Depression
• Fatigue
• Frequent Yawning
• Hyperactivity
• Irritability
• Neck Stiffness
• Others

On the basis of symptoms, the migraine market is segmented into food cravings, depression, fatigue, frequent yawning, hyperactivity, irritability, neck stiffness, and others.

Treatment

• Medication
• Acupressure
• Counseling
• Hormone Therapy
• Others

On the basis of treatment, the global migraine market is segmented into medication, acupressure, counseling, hormone therapy and others. Medication segment is further segmented into pain-relieving medications, and preventive medications. Pain-relieving medications are further sub-segmented into anti-nausea drugs, opioid medications, CGRP antagonists, ubrogepant, lasmiditan, dihydroergotamine, triptans, and pain relievers. Preventive medications are further sub-segmented into CGRP monoclonal antibodies, botox injections, anti-seizure drugs, antidepressants, and blood pressure-lowering medications.

Diagnosis

• Computerized Tomography (CT) Scan
• Magnetic Resonance Imaging (MRI)
• Others

On the basis of diagnosis, the migraine market is segmented into computerized tomography (CT) scan, magnetic resonance imaging (MRI), and others.

Route of Administration

• Oral
• Parenteral
• Others

The route of administration segment for the migraine market is segmented into oral, parenteral and others.

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

On the basis of end-users, the migraine market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

On the basis of distribution channel, the migraine market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.

Migraine Market Regional Analysis/Insights

The Migraine market is analysed and market size insights and trends are provided by country, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Migraine market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the migraine market because of the growing prevalence of migraine in this region. Additionally, growing focus of major key players on novel technology will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to rise in the number of population and rising healthcare expenditure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Migraine Market Share Analysis

편두통 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 프로그램 우세입니다. 위에 제공된 데이터 포인트는 편두통 시장과 관련된 회사의 초점에만 관련이 있습니다.

편두통 시장의 주요 업체는 다음과 같습니다.

• F. 호프만-라 로슈 유한회사(스위스)
• 마일런 NV(미국)
• Teva Pharmaceutical Industries Ltd.(예루살렘)
• 사노피(프랑스)
• 파이저 주식회사(미국)
• GlaxoSmithKline plc (영국)
• 노바티스 AG(스위스)
• Bayer AG(독일)
• 엘리 릴리 앤드 컴퍼니(미국)
• 머크앤코(미국)
• 알러간(아일랜드)
• 아스트라제네카(영국)
• AbbVie Inc.(미국)
• WOCKHARDT(뭄바이)
• 존슨앤존슨 프라이빗 리미티드(미국)
• 시플라 주식회사(미국)  
• Amneal Pharmaceuticals LLC. (미국)
• 에자이 주식회사(일본)
• Bausch Health Companies Inc. (캐나다)
• 애벗(미국)
• 다케다제약 주식회사(일본)
• 머크 KGaA(독일)

SKU-53134